Intellia Q3 Loss Widens to $127.5 Million as Launch Costs Rise

Intellia Therapeutics (NTLA ) reported third-quarter results on November 5, 2026, showing a net loss of $127.5 million, up from $101.3 million in the third quarter of 2025. Higher commercial-launch spending and lower collaboration revenue offset a reduction in research costs, while an investment-valuation swing added to the bottom-line decline.

For the quarter ended September 30, 2026, collaboration revenue fell to $7.2 million from $13.8 million, primarily because of reduced revenue from Regeneron. Research and development expense declined to $83.3 million from $94.7 million, partly reflecting lower external costs related to lonvo-z.

Those research savings were more than absorbed by the commercial buildout. General and administrative expense climbed to $46.1 million from $30.5 million, driven primarily by consulting costs associated with commercial infrastructure, alongside higher legal, facility-related and compensation expenses. Total operating expenses consequently rose to $129.5 million from $125.3 million.

The wider loss also reflected a $10.4 million unrealized loss on investments, compared with a $3.4 million unrealized gain in the comparable 2025 quarter. Both resulted from changes in the fair value of investments. That swing compounded the pressure from lower revenue and the administrative costs of preparing for a product launch.

Cash Runway Excludes Further Loan Funding

Cash, cash equivalents and marketable securities totaled $614.8 million at September 30, 2026, compared with $605.1 million at December 31, 2025. Intellia expects its existing cash resources to fund operations at least into 2028 and well beyond lonvo-z’s anticipated approval and commercial launch.

That forecast excludes all potential commercial revenue from lonvo-z and any future funding from the company’s term-loan facility. The distinction matters because the facility’s headline capacity is not entirely funded or unconditionally available.

Intellia’s September 4, 2026 financing announcement detailed a non-dilutive senior secured term-loan facility with OrbiMed for up to $400 million. Only $75 million was funded at closing. Five additional tranches totaling up to $225 million can be drawn at Intellia’s option, subject primarily to achieving specified lonvo-z milestones. A further $100 million requires mutual agreement between the parties during the agreement’s five-year term. The additional capacity therefore depends on clinical or regulatory progress and, for the final portion, a separate agreement with the lender.

Lonvo-Z Launch Spending Precedes FDA Decision

The administrative buildout is tied to a defined regulatory timetable. In September 2026, the U.S. Food and Drug Administration accepted the Biologics License Application for lonvo-z and granted it Priority Review, setting a March 10, 2027 target action date. The FDA advised that it was not currently planning an advisory-committee meeting to discuss the application, which remains under review.

Intellia is preparing for a planned first-quarter 2027 launch for hereditary angioedema, or HAE. It has completed deployment of its field organization and is expanding engagement with treatment centers and payers.

Lonvo-z is designed as a one-time, outpatient-administered in-vivo CRISPR treatment intended to inactivate the KLKB1 gene, permanently lowering kallikrein and bradykinin levels. Chief Executive John Leonard said Intellia was working toward “a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy.”

Nex-Z Enrollment Defines the Next Clinical Workload

On November 4, 2026, Intellia separately announced completion of enrollment in MAGNITUDE-2, its Phase 3 trial of nex-z in hereditary transthyretin amyloidosis with polyneuropathy. Randomization exceeded the 60-patient target.

The randomized, double-blind, placebo-controlled study assigned adults 1:1 to receive either a single 55 mg infusion of nex-z or placebo. Its primary endpoints are the change in modified neuropathy impairment score at month 18 and the change in serum TTR levels at day 29. Patients can enter an optional blinded crossover after month 18.

Nex-z is designed to inactivate the TTR gene in the liver, preventing production of transthyretin protein. It is also being evaluated in the separate MAGNITUDE Phase 3 trial in ATTR amyloidosis with cardiomyopathy, where enrollment is advancing. Intellia leads development and commercialization in collaboration with Regeneron, linking this late-stage program to the partnership behind the collaboration-revenue comparison.

The results place Intellia between development and commercialization: quarterly research costs are falling, but launch infrastructure and two Phase 3 nex-z trials remain substantial operational commitments. Management’s runway extends beyond the planned lonvo-z launch without assuming product revenue or additional loan draws, leaving the FDA decision, launch execution and milestone-based access to further financing as the next checkpoints.